TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04025294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: videogame
Description: A videogame intervention that is interactive and engaging that teaches adolescents how to restructure negative automatic thoughts through an adapted thought record (a technique used in cognitive behavioral therapy to improve moods) by modeling how to do so and then empower them through real-life activities to improve their school climate. The videogame intervention is comprised of five mini-games, each containing a short narrative that models how to restructure negative automatic thoughts and navigate through challenging situations that often take place in school settings. The topics of each mini-game are informed by the constructs of school climate according to the National School Climate Center. Students using the videogame intervention will be prompted to think deeply and reflect on the narratives presented in each mini-game.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School Climate Assessment Survey
Description: A school climate assessment survey will include items adapted from questions developed by the National School Climate Center. Items will assess various dimensions of school climate including safety, social media, relationships, support for learning, and environment.
Study: NCT02969876

Intervention type: DRUG
Group type: OTHER
Intervention: Vortioxetine
Description: Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
Study: NCT03414281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMQLB group 1
Description: The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMQLB group 2
Description: The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB
Description: The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe of Philips CX50 is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the paravertebral space of T10.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
Study: NCT04137029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: The participants will receive inhalation of formoterol 12 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: The participants will receive inhalation of formoterol 12 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: The participants will receive inhalation of tiotropium bromide 18 mkg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: The participants will receive inhalation of tiotropium bromide 18 mkg once

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: metacholine test
Description: The participants will receive inhalation of metacholine once

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: metacholine test
Description: The participants will receive inhalation of metacholine once
Study: NCT00631696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 600 mg given twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00002854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT04088643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation
Description: The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
Study: NCT02777619

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.0ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.0ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.4ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.6ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.8ng/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study: NCT04452032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental avulsion
Description: Before radiotherapy, each subject undergoes a dental evaluation and if it is necessary, dental avulsions if their long-term survival is compromised (see in section 6.1.2) and if they are located in an area at risk to receive more than 40 Gy, so to develop osteoradionecrosis of the jaw. The avulsions should be performed as far as possible from the start of radiotherapy (RT) namely at least 2 weeks before irradiation to allow mucosal healing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy:~All Subjects will be treated by simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT) / volumetric modulated arc therapy (VMAT).
Study: NCT02704260

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GENETIC ANALYSIS
Description: prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
Study: NCT01160211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1000 mg by mouth once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: 1500 mg by mouth once daily
Study: NCT00676338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2mg, once weekly plus placebo oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: oral, 100 mg, daily plus placebo once weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
Study: NCT01699490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Valsartan
Description: The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine + Placebo
Description: The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
Study: NCT04238416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched chain amino acid
Description: Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Oral lactulose will be given to patients in both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Oral lactulose will be given to patients in both arms
Study: NCT04226560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 41% Silicone Hydrogel Soft Contact Lenses(SHSCL)
Description: Silicone Hydrogel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens
Description: Senofilcon C (USFDA Device License #K160212)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact Lens Care Product
Description: Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contact Lens Care Product
Description: Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact Lens Case
Description: Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contact Lens Case
Description: Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)
Study: NCT01826773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CardioPET™
Description: CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CardioPET™
Description: CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
Study: NCT03719443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIS649
Description: Single IV dose of study product on Day 1 of study

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Singe IV dose of placebo administered via IV on Day 1 of study
Study: NCT04053179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch validation
Description: Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
Study: NCT03312777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnitram
Description: Omnitram tablets overencapsulated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol tablet overencapsulated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline powder overencapsulated
Study: NCT04165798

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor Imaging
Description: Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.

Intervention type: PROCEDURE
Intervention: Tumor Tissue Collection
Description: Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.

Intervention type: PROCEDURE
Intervention: Blood Sample Collection
Description: Participants will have blood samples drawn for analysis of:~* genetics~* ribonucleic acid (RNA)~* serum biomarker~* plasma biomarker~* circulating tumor DNA (ctDNA)
Study: NCT00657280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: No one is blinded to the treatments.
Study: NCT03363256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TES-NAV
Description: Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
Study: NCT03549455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy and Self Distancing
Description: Weeks 1 and 2 will be introductory sessions (background, rationale, motivational enhancement); Weeks 3 \& 4 will have Exposure therapy with Self-Distancing; Weeks 5 \& 6 will have Exposure therapy only; Weeks 7 \& 8 will have Exposure therapy with Self-Distancing;
Study: NCT03363256

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard outpatient addiction treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Standard outpatient addiction treatment
Study: NCT03244176

Intervention type: DRUG
Group type: OTHER
Intervention: Avelumab
Description: All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles.
Study: NCT03059082

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recovery Navigator on an as needed basis up to 6 months
Description: This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months and then have a 3 month and 6 month follow-up visit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recovery Navigator prior to hospital discharge
Description: This group will undergo one interaction with Recovery Navigator prior to hospital discharge and then have a 3 month and 6 month follow-up visit.

Intervention type: OTHER
Group type: OTHER
Intervention: No interaction with Recovery Navigator
Description: This group will not have any interaction with Recovery Navigator. They will have a 3 month and 6 month follow-up visit.
Study: NCT04708743

Intervention type: DIAGNOSTIC_TEST
Intervention: Automatic Tongue Diagnosis System
Description: tongue image capture tongue images by Automatic Tongue Diagnosis System

Intervention type: DIAGNOSTIC_TEST
Intervention: Automatic Tongue Diagnosis System
Description: tongue image capture tongue images by Automatic Tongue Diagnosis System
Study: NCT00941031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457A
Description: Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457A
Description: Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9
Study: NCT03015831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine will be given to open heart surgery patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet will be given to open heart surgery patients according to randomization
Study: NCT01611909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p-menthane-3,8-diol oil
Description: Apply topically to affected area twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p-menthane-3,8-diol oil
Description: Apply topically to affected area twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: p-menthane-3,8-diol oil
Description: Apply topically to affected area twice daily
Study: NCT00803426

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic nerve blockade for ankle/foot surgery
Description: Injection of local anesthetic near the nerve to achieve anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve blockade for ankle/foot surgery
Description: Injection of local anesthetic near the nerve to achieve anesthesia.
Study: NCT02261870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI T2 quantification
Description: MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
Study: NCT00983476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in-person MOVE! SMI
Description: Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based MOVE! SMI
Description: online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
Study: NCT01363466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysterectomy
Study: NCT02722616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound scan of the pancreas
Description: A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound scan of the Liver
Description: A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.

Intervention type: DRUG
Group type: OTHER
Intervention: Reference ultrasound
Description: A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
Study: NCT00535028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AER 001
Description: AER 001 25 mgs s.c. once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sterile saline
Study: NCT01477099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrushing with a manual brush
Description: Toothbrushing with a manual brush
Study: NCT05317962

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiogram
Description: Abbreviated transthoracic echocardiogram
Study: NCT04407832

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heat probe or hemoclip
Description: for hemostasis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heat probe or hemoclip
Description: for hemostasis